Published in Biochim Biophys Acta on April 18, 2013
Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. Biochim Biophys Acta (2014) 1.01
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Curr Alzheimer Res (2016) 0.90
Redox proteomics analysis of HNE-modified proteins in Down syndrome brain: clues for understanding the development of Alzheimer disease. Free Radic Biol Med (2014) 0.89
The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation. Neurobiol Dis (2013) 0.88
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta (2014) 0.88
Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics. Proteomics Clin Appl (2014) 0.86
Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in Down's syndrome and Alzheimer's disease brain. Biochem J (2014) 0.83
It Is All about (U)biquitin: Role of Altered Ubiquitin-Proteasome System and UCHL1 in Alzheimer Disease. Oxid Med Cell Longev (2016) 0.82
The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment. Free Radic Biol Med (2014) 0.81
Neuronal failure in Alzheimer's disease: a view through the oxidative stress looking-glass. Neurosci Bull (2014) 0.81
Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress. PLoS One (2014) 0.77
Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype. J Alzheimers Dis (2016) 0.76
Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-a system: insights for transition to Alzheimer's disease. J Alzheimers Dis (2015) 0.76
Essential role of proteasomes in maintaining self-renewal in neural progenitor cells. Sci Rep (2016) 0.76
Poly-Ubiquitinylation Profile in Down Syndrome Brain before and after the Development of Alzheimer Neuropathology. Antioxid Redox Signal (2016) 0.75
A Comprehensive Diverse '-omics' Approach to Better Understanding the Molecular Pathomechanisms of Down Syndrome. Brain Sci (2017) 0.75
Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce β-Amyloid Production and Improve Cognitive Impairments. PLoS One (2016) 0.75
Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics (2016) 0.75
One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol (2008) 8.68
mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science (2011) 7.55
Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations. Cell (2010) 5.09
Endoplasmic reticulum stress triggers autophagy. J Biol Chem (2006) 5.05
ER stress and diseases. FEBS J (2007) 5.03
Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol (2007) 4.45
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet (2006) 4.01
Molecular profile of reactive astrocytes--implications for their role in neurologic disease. Neuroscience (1993) 3.51
Activation of chaperone-mediated autophagy during oxidative stress. Mol Biol Cell (2004) 3.26
GFAP in health and disease. Prog Neurobiol (2011) 2.65
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol Med (2001) 2.63
The unfolded protein response regulator GRP78/BiP is required for endoplasmic reticulum integrity and stress-induced autophagy in mammalian cells. Cell Death Differ (2008) 2.53
Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med (2005) 2.51
Degradation of oxidized proteins in mammalian cells. FASEB J (1997) 2.51
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology (2007) 2.51
Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem (2004) 2.46
Impaired proteasome function in Alzheimer's disease. J Neurochem (2000) 2.44
Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature (1996) 2.29
Cathepsin D--many functions of one aspartic protease. Crit Rev Oncol Hematol (2008) 2.26
Protein quality control: chaperones culling corrupt conformations. Nat Cell Biol (2005) 2.20
Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci (2000) 2.10
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med (2002) 2.10
Identification of regulators of chaperone-mediated autophagy. Mol Cell (2010) 1.92
Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging (2004) 1.88
Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron (2002) 1.82
Proteolysis in cultured liver epithelial cells during oxidative stress. Role of the multicatalytic proteinase complex, proteasome. J Biol Chem (1995) 1.79
Protein misfolding and neurodegeneration. Arch Neurol (2008) 1.78
Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology (1985) 1.75
Role of mutant SOD1 disulfide oxidation and aggregation in the pathogenesis of familial ALS. Proc Natl Acad Sci U S A (2009) 1.67
Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron (1995) 1.58
Genetic and host factors for dementia in Down's syndrome. Br J Psychiatry (2002) 1.42
Amyloid precursor protein (APP) traffics from the cell surface via endosomes for amyloid β (Aβ) production in the trans-Golgi network. Proc Natl Acad Sci U S A (2012) 1.38
Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis (2007) 1.32
Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects. Am J Pathol (2008) 1.28
Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res (2011) 1.26
Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol (1998) 1.24
Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal (2012) 1.24
Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia (1989) 1.22
The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect (2007) 1.21
The ubiquitin-proteasome pathway and synaptic plasticity. Learn Mem (2010) 1.20
Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev (2001) 1.20
Lysosomal proteinase antigens are prominently localized within senile plaques of Alzheimer's disease: evidence for a neuronal origin. Brain Res (1990) 1.18
Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat Rev Drug Discov (2012) 1.18
Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res Rev (2009) 1.18
Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One (2011) 1.17
Autophagy as a cell-repair mechanism: activation of chaperone-mediated autophagy during oxidative stress. Mol Aspects Med (2006) 1.15
Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation. Braz J Med Biol Res (1999) 1.10
The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol (1987) 1.09
Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. J Alzheimers Dis (2007) 1.08
IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments. Oncogene (2012) 1.07
Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res (2005) 1.06
Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. Mol Aspects Med (2011) 1.05
The role of the ubiquitin proteasome system in Alzheimer's disease. Exp Biol Med (Maywood) (2011) 1.05
Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment. J Bioenerg Biomembr (2009) 1.05
Removing protein aggregates: the role of proteolysis in neurodegeneration. Curr Med Chem (2011) 1.04
Exposure of hydrophobic moieties promotes the selective degradation of hydrogen peroxide-modified hemoglobin by the multicatalytic proteinase complex, proteasome. Arch Biochem Biophys (1994) 1.04
Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta (2011) 1.02
Proteomic analysis of glial fibrillary acidic protein in Alzheimer's disease and aging brain. Neurobiol Dis (2005) 1.01
Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia. Curr Gerontol Geriatr Res (2011) 0.98
Down syndrome and beta-amyloid deposition. Curr Opin Neurol (2004) 0.98
Oxidative stress occurs early in Down syndrome pregnancy: A redox proteomics analysis of amniotic fluid. Proteomics Clin Appl (2011) 0.98
Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard (1997) 0.98
Protein quality control in neurodegenerative disease. Prog Mol Biol Transl Sci (2012) 0.97
Early glycoxidation damage in brains from Down's syndrome. Biochem Biophys Res Commun (1998) 0.96
Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol Chem (2008) 0.96
Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD. J Proteome Res (2009) 0.96
The unfolded protein response and proteostasis in Alzheimer disease: preferential activation of autophagy by endoplasmic reticulum stress. Autophagy (2011) 0.95
Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis (2006) 0.95
Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis (2011) 0.94
Oxidative stress and mitochondrial dysfunction in Down syndrome. Adv Exp Med Biol (2012) 0.93
Protein homeostasis, aging and Alzheimer's disease. Mol Neurobiol (2012) 0.93
Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis (2010) 0.93
NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis. Curr Pharm Des (2007) 0.92
The effect of mixed-function oxidation of enzymes on their susceptibility to degradation by a nonlysosomal cysteine proteinase. Arch Biochem Biophys (1985) 0.92
Autophagy in aging and Alzheimer's disease: pathologic or protective? J Alzheimers Dis (2011) 0.89
Cathepsin D is one of the major enzymes involved in intracellular degradation of AGE-modified proteins. Free Radic Res (2010) 0.88
Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease. Antioxid Redox Signal (2012) 0.88
Cathepsin D gene and the risk of Alzheimer's disease: a population-based study and meta-analysis. Neurobiol Aging (2009) 0.87
Differential susceptibility to neurofibrillary pathology among patients with Down syndrome. Dementia (1996) 0.86
Increased Abeta1-42 production sensitizes neuroblastoma cells for ER stress toxicity. Curr Alzheimer Res (2008) 0.86
An altered antioxidant balance occurs in Down syndrome fetal organs: implications for the "gene dosage effect" hypothesis. J Neural Transm Suppl (2003) 0.82
Cathepsins D and L reduce the toxicity of advanced glycation end products. Free Radic Biol Med (2012) 0.82
Immunodetection of cathepsin D in neuritic plaques found in brains of patients with dementia of Alzheimer type. J Hirnforsch (1989) 0.81
Roles of ubiquitin in endoplasmic reticulum-associated protein degradation (ERAD). Curr Protein Pept Sci (2012) 0.79
Free radical damage in Down's syndrome brain. Biochem Soc Trans (1993) 0.79
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat Rev Neurosci (2007) 2.77
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice--a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med (2005) 2.51
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A (2002) 2.28
Histone deacetylase and Cullin3-REN(KCTD11) ubiquitin ligase interplay regulates Hedgehog signalling through Gli acetylation. Nat Cell Biol (2010) 2.25
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med (2002) 2.10
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology (2008) 1.94
Retracted Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun (2008) 1.91
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid beta-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging (2003) 1.78
Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv (2007) 1.74
APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology (2009) 1.74
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part II: dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem (2002) 1.73
Proteomic identification of nitrated proteins in Alzheimer's disease brain. J Neurochem (2003) 1.70
The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J Neurochem (2003) 1.67
Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front Biosci (2007) 1.65
Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J Neurol Sci (2005) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol Dis (2005) 1.58
Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol (2006) 1.57
Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci (2009) 1.54
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem (2011) 1.53
Retracted Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem (2009) 1.53
Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD. Neurobiol Aging (2005) 1.52
Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis (2002) 1.51
Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis. Neurobiol Aging (2005) 1.50
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci U S A (2010) 1.45
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis (2010) 1.41
Nutrition, brain aging, and neurodegeneration. J Neurosci (2009) 1.40
Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis (2008) 1.38
Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem (2003) 1.38
Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett (2006) 1.38
Nitric oxide in cell survival: a janus molecule. Antioxid Redox Signal (2009) 1.37
Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antioxid Redox Signal (2006) 1.37
Ferulic acid ethyl ester protects neurons against amyloid beta- peptide(1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem (2005) 1.37
Ferulic acid antioxidant protection against hydroxyl and peroxyl radical oxidation in synaptosomal and neuronal cell culture systems in vitro: structure-activity studies. J Nutr Biochem (2002) 1.35
Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging (2002) 1.34
Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegener (2010) 1.34
Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer's disease. Brain Behav Immun (2009) 1.32
Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem (2003) 1.32
Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis (2007) 1.32
The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis (2008) 1.31
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. J Neurosci (2007) 1.31
Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. J Neurotrauma (2007) 1.30
Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav (2007) 1.28
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
Cellular stress response: a novel target for chemoprevention and nutritional neuroprotection in aging, neurodegenerative disorders and longevity. Neurochem Res (2008) 1.26
Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol Cell Proteomics (2005) 1.25
Protective effect of quercetin in primary neurons against Abeta(1-42): relevance to Alzheimer's disease. J Nutr Biochem (2008) 1.25
Oxidative stress and cellular stress response in diabetic nephropathy. Cell Stress Chaperones (2007) 1.25
Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging (2005) 1.24
Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal (2012) 1.24
An increase in S-glutathionylated proteins in the Alzheimer's disease inferior parietal lobule, a proteomics approach. J Neurosci Res (2007) 1.23
Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E epsilon2/epsilon2 genotype. Arch Neurol (2007) 1.22
Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD. Brain Res (2009) 1.22
Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis (2006) 1.22
Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res (2007) 1.21
Measurement of oxidized/reduced glutathione ratio. Methods Mol Biol (2010) 1.20
Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol (2006) 1.20
Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal (2006) 1.20
Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology (2008) 1.20
Free radicals and brain aging. Clin Geriatr Med (2004) 1.20
Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem (2007) 1.19
Locomotor activity rhythms in dogs vary with age and cognitive status. Behav Neurosci (2003) 1.19
Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis (2010) 1.19
Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci (2008) 1.18
Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain. Free Radic Biol Med (2012) 1.18
Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol Biol (2010) 1.18
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging (2006) 1.17
BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem (2009) 1.16
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm (Vienna) (2009) 1.14